Impact of technology in sterile intravenous compounding
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/jqca8279 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Jannette Cruz Vallellanes. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Sterile intravenous (IV) compounding is a critical pharmacy practice that demands precision, safety, and compliance with United States Pharmacopeia (USP) and USP standards. Traditional manual compounding, while effective, is associated with risks such as contamination, human error, and inefficient workflow. Emerging technologies are transforming this field by enhancing accuracy, traceability, and safety in both hazardous and non-hazardous compounding environments.
Zitieren
APA
Vallellanes, J. C. (2026). Impact of technology in sterile intravenous compounding. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/jqca8279
Vancouver
Vallellanes JC. Impact of technology in sterile intravenous compounding. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/jqca8279
BibTeX
@article{Vallellanes2026,
author = {Vallellanes, Jannette Cruz},
title = {Impact of technology in sterile intravenous compounding},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/jqca8279}
}
EUVIMED